Patient Capital Management’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RPRX
Patient Capital Management's RPRX Position: Q2 2026 in Review
Patient Capital Management reduced its Royalty Pharma (RPRX) stake by 1.2% in Q2 2026, selling an estimated $2.34M and leaving 3,598,808 shares worth $202M. The position accounts for 6.61% of the portfolio, ranked #1.
Patient Capital Management first reported a position in RPRX in Q4 2023 and has held it in 11 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.
- Patient Capital Management held 3,598,808 shares of Royalty Pharma worth $202M as of Q2 2026.
- Patient Capital Management sold 44,908 Royalty Pharma shares in Q2 2026, an estimated $2.34M.
- Royalty Pharma made up 6.61% of Patient Capital Management's portfolio in Q2 2026, its #1 holding.
- Patient Capital Management first reported a position in Royalty Pharma in Q4 2023 and has held it in 11 quarters since.
- 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.
Based on Patient Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.